Merus BV (MRUS NASDAQ) stock market data APIs
$96.3103
0.13(0.1%)
as of December 12, 2025
Try our APIs with
free plan!
Merus BV Financial Data Overview
Price chart is built with
Anychart
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Prev. Close
96.3103
Open
97.3467
High
97.7512
Low
96.1388
52 wk Range
33.19-96.94
Market Cap
7 352 M
Shares Outstanding
75 847 K
Revenue
56 606 K
EPS
-1.26
Beta
1.062
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Merus BV (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merus BV data using free add-ons & libraries
Get Merus BV Fundamental Data
Merus BV Fundamental data includes:
- Net Revenue: 56 606 K
- EBITDA: -368 772 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -1.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merus BV News
New
Genmab Meets Conditions For $97/shr Merus Tender Offer
(RTTNews) - Genmab A/S (GMAB), a Danish biotechnology company's subsidiary, Genmab Holding II B.V., announced on Friday that the conditions to its tender offer to acquire all Merus N.V. (MRUS) shares ...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA ...
How Genmab’s US$2.5 Billion Merus Deal Financing Could Impact Genmab (CPSE:GMAB) Investors
In early December 2025, Genmab A/S completed a US$1.50 billion offering of 6.250% senior secured notes due 2032 and US$1.00 billion of 7.250% senior unsecured notes due 2033, alongside new credit fa...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
